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Summary
Background Clinical use of criteria for metabolic syndrome to simultaneously predict risk of cardiovascular disease 
and diabetes remains uncertain. We investigated to what extent metabolic syndrome and its individual components 
were related to risk for these two diseases in elderly populations.
Methods We related metabolic syndrome (deﬁ ned on the basis of criteria from the Third Report of the National 
Cholesterol Education Program) and its ﬁ ve individual components to the risk of events of incident cardiovascular 
disease and type 2 diabetes in 4812 non-diabetic individuals aged 70–82 years from the Prospective Study of Pravastatin 
in the Elderly at Risk (PROSPER). We corroborated these data in a second prospective study (the British Regional 
Heart Study [BRHS]) of 2737 non-diabetic men aged 60–79 years.
Findings In PROSPER, 772 cases of incident cardiovascular disease and 287 of diabetes occurred over 3·2 years. 
Metabolic syndrome was not associated with increased risk of cardiovascular disease in those without baseline disease 
(hazard ratio 1·07 [95% CI 0·86–1·32]) but was associated with increased risk of diabetes (4·41 [3·33–5·84]) as was 
each of its components, particularly fasting glucose (18·4 [13·9–24·5]). Results were similar in participants with 
existing cardiovascular disease. In BRHS, 440 cases of incident cardiovascular disease and 105 of diabetes occurred 
over 7 years. Metabolic syndrome was modestly associated with incident cardiovascular disease (relative risk 1·27 
[1·04–1·56]) despite strong association with diabetes (7·47 [4·90–11·46]). In both studies, body-mass index or waist 
circumference, triglyceride, and glucose cutoﬀ  points were not associated with risk of cardiovascular disease, but all 
ﬁ ve components were associated with risk of new-onset diabetes.
Interpretation Metabolic syndrome and its components are associated with type 2 diabetes but have weak or no 
association with vascular risk in elderly populations, suggesting that attempts to deﬁ ne criteria that simultaneously 
predict risk for both cardiovascular disease and diabetes are unhelpful. Clinical focus should remain on establishing 
optimum risk algorithms for each disease.
Funding Diabetes UK and British Heart Foundation.
Introduction
Criteria for metabolic syndrome were developed to 
improve understanding of links between insulin 
resistance and vascular disease; however, their clinical 
role, which was designed to predict people at risk of 
events of cardiovascular disease or diabetes, remains 
contentious. Although metabolic syndrome is associated 
with increased risk for incident vascular events in 
middle-aged populations with or without existing 
coronary heart disease,1–3 the amount of association is 
modest. A recent meta-analysis4 showed around a 
50% higher risk for coronary heart disease in patients 
with metabolic syndrome compared with those without, 
after adjustment for traditional risk factors of coronary 
heart disease. This hazard ratio (HR) is, at best, modest 
and thus when tested with receiver operating 
characteristic (ROC) analyses, criteria for metabolic 
syndrome in middle-aged populations do less well than 
do traditional risk algorithms—eg, Framingham risk 
score—and do not enhance risk prediction.3,5 Further-
more, the criteria for metabolic syndrome do not oﬀ er 
more than the sum of its parts.6,7 These observations 
have led several investigators to question the value of a 
formal diagnosis of metabolic syndrome in clinical 
practice8–11 for determination of vascular risk.
Yet, despite such ﬁ ndings, research using criteria for 
metabolic syndrome as an entity to establish vascular 
risk continues unabated,12–14 with conclusions that are 
often potentially misplaced or overstated. Moreover, few 
studies have simultaneously linked metabolic syndrome 
to risk for both incident diabetes and coronary heart 
disease, to establish whether prediction of both endpoints 
can be usefully achieved by one set of criteria. 
We addressed these issues in two prospective studies 
in elderly populations—namely, the Prospective Study of 
Pravastatin in the Elderly at Risk (PROSPER)15 and the 
British Regional Heart Study (BRHS).16 BRHS helped us 
to corroborate and generalise our ﬁ ndings in PROSPER. 
Lancet 2008; 371: 1927–35
Published Online
May 22, 2008
DOI:10.1016/S0140-
6736(08)60602-9
See Comment page 1892
Faculty of Medicine 
(Prof N Sattar FRCPath, 
D J Freeman PhD, 
Prof P W Macfarlane DSc, 
Prof C J Packard DSc, 
Prof D J Stott MD, 
Prof J Shepherd MD) and 
Robertson Centre for 
Biostatistics 
(A McConnachie PhD, 
Prof I Ford PhD), University of 
Glasgow, Glasgow, UK; MRC 
Epidemiology Unit, Institute of 
Metabolic Science, 
Addenbrookes Hospital, 
Cambridge, UK 
(N G Forouhi FFPH); 
Department of Pharmacology 
and Therapeutics, Cork 
University Hospital, Wilton, 
Cork, Ireland 
(Prof B M Buckley FRCPI, 
Prof M B Murphy MD); Section 
of Gerontology and Geriatrics 
(G J Blauw MD, A J de Craen PhD, 
Prof R G Westendorp MD) and 
Departments of Cardiology 
(Prof J W Jukema MD), Leiden 
University Medical Centre, 
Leiden, Netherlands; 
Department of Primary Care and 
Population Sciences, Royal Free 
and University College Medical 
School, London, UK 
(Prof A G Shaper FRCP, 
S G Wannamethee PhD, 
L Lennon MSc); and Division of 
Community Health Sciences, 
St George’s, University of 
London, London, UK 
(Prof P H Whincup FRCP)
Correspondence to:
Prof Naveed Sattar, Faculty of 
Medicine, BHF Glasgow 
Cardiovascular Research Centre, 
126 University Place, University of 
Glasgow, Glasgow G12 8TA, UK
nsattar@clinmed.gla.ac.uk
Articles
1928 www.thelancet.com   Vol 371   June 7, 2008
In both prospective studies, all components of the 
metabolic syndrome were available at baseline (body-mass 
index [BMI] replacing waist circumference in PROSPER, 
as previously validated2), and importantly, both studies 
had ascertained events of incident cardiovascular disease 
and type 2 diabetes, which is a fairly uncommon feature 
in prospective studies. Therefore, we were able to 
establish to what extent metabolic syndrome and its 
individual components were related to risk for 
cardiovascular events (fatal and non-fatal) and to risk for 
incident type 2 diabetes in elderly people. We hypothesised 
that metabolic syndrome would be weakly associated 
with risk of incident cardiovascular disease despite being 
strongly associated with risk of incident diabetes in both 
cohorts.
Methods
The Prospective Study of Pravastatin in the Elderly at 
Risk (PROSPER)
The protocol of PROSPER17 and the methods and 
outcomes of the main trial have been published.15
Between Dec 15, 1997, and May 7, 1999, we screened 
23 770 individuals and enrolled 5804 from Scotland, 
Ireland, and the Netherlands. Men and women aged 
70–82 years were recruited if they had either pre-existing 
vascular disease (coronary, cerebral, or peripheral) or 
raised risk of such disease because of smoking, 
hypertension, or diabetes. Their plasma total cholesterol 
had to be between 4·0–9·0 mmol/L and their fasting 
triglyceride concentrations less than 6·0 mmol/L. The 
institutional ethics review boards of all centres approved 
the protocol, and all participants gave written informed 
consent. The protocol was consistent with the Declaration 
of Helsinki.
Participants were randomly assigned to receive either 
pravastatin 40 mg daily or matching placebo.15 We 
reviewed participants every 3 months, over a mean 
follow-up of 3·2 (range 2·8–4·0) years. All data were 
processed and analysed at The Robertson Centre for 
Biostatistics in Glasgow (UK). The primary outcome of 
the original trial was the combined endpoint of deﬁ nite 
or suspected death from coronary heart disease, non-fatal 
myocardial infarction, and fatal or non-fatal stroke, which 
were all labelled under the term cardiovascular disease. 
All events were adjudicated by an independent review 
board.
Participants with known or newly diagnosed diabetes 
at baseline were excluded from the present analyses. 
Diabetes at baseline was deﬁ ned by self-reported history, 
a fasting blood glucose concentration of 7·0 mmol/L or 
greater or a blood glucose measurement of 11·1 mmol/L 
or greater when fasting status was uncertain, or 
Incident CVD Incident diabetes
Absent (n=4040) Present (n=772) p value Absent (n=4525) Present (n=287) p value
Age (years) 75·3 (3·3) 75·7 (3·5) 0·003 75·4 (3·4) 75·3 (3·3) 0·95
BMI (kg/m2) 26·7 (4·2) 26·5 (3·9) 0·18 26·5 (4·1) 28·7 (4·4) <0·0001
Systolic BP (mm Hg) 154·0 (21·7) 154·8 (22·4) 0·35 153·9 (21·7) 156·6 (23·5) 0·045
Diastolic BP (mm Hg) 83·9 (11·4) 82·8 (11·5) 0·018 83·7 (11·4) 84·2 (12·2) 0·46
Fasting glucose (mmol/L)* 5·02 (1·12) 5·01 (1·12) 0·60 4·97 (1·12) 5·81 (1·13) <0·0001
Total cholesterol (mmol/L)* 5·66 (1·17) 5·63 (1·16) 0·42 5·66 (1·17) 5·64 (1·17) 0·81
HDL cholesterol (mmol/L)* 1·26 (1·30) 1·22 (1·30) 0·0003 1·26 (1·30) 1·16 (1·31) <0·0001
LDL cholesterol (mmol/L)* 3·74 (1·24) 3·76 (1·22) 0·63 3·75 (1·24) 3·72 (1·22) 0·58
Triglyceride (mmol/L)* 1·38 (1·51) 1·40 (1·51) 0·32 1·37 (1·50) 1·63 (1·56) <0·0001
Men 1811 (45%) 441 (57%) <0·0001 2108 (47%) 144 (50%) 0·26
Smoking
Never 1391 (34%) 232 (30%) 1518 (34%) 105 (37%)
Former 1523 (38%) 308 (40%) 1713 (38%) 118 (41%)
Current 1126 (28%) 232 (30%) 0·061 1294 (29%) 64 (22%) 0·071
History of:
Hypertension 2575 (64%) 445 (58%) 0·002 2818 (62%) 202 (70%) 0·007
Coronary artery disease 1203 (30%) 345 (45%) <0·0001 1450 (32%) 98 (34%) 0·50
Peripheral arterial disease 394 (10%) 136 (18%) <0·0001 500 (11%) 30 (11%) 0·83
Stroke or TIA 453 (11%) 116 (15%) 0·003 538 (12%) 31 (11%) 0·65
Any vascular disease 1714 (42%) 456 (59%) <0·0001 2047 (45%) 123 (43%) 0·47
Data are mean (SD) or number (%). CVD=cardiovascular disease. BMI=body-mass index. BP=blood pressure. TIA=transient ischaemic attack. p values for continuous variables 
are from two-sample t test and for categorical variables from χ² test. *Values are geometric means (SD) calculated from the log-transformed distribution. †Because of the 
design structure of the trial—which recruited more participants with hypertension, diabetes, or smokers into the low-risk primary prevention group—the signiﬁ cance or 
non-signiﬁ cance of some univariate comparisons in this table should be examined with caution. 
Table 1: Comparison of baseline characteristics in participants who subsequently had an incident cardiovascular event or new-onset diabetes in the 
Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)†
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self-reported use of antidiabetic drugs (any oral 
hypoglycaemic agent or insulin).
Incident diabetes during the trial was deﬁ ned by the 
same criteria; the incidence date was assigned as the date 
of the study visit at which the criteria were satisﬁ ed. 
Glucose measurements throughout the study were 
fasting in more than 95% of participants and thus most 
diagnoses were based on criteria for fasting glucose.
Baseline characteristics were compared between 
participants who did or did not experience the two 
endpoints (cardiovascular disease or diabetes) during 
follow-up. Participants were classiﬁ ed according to ﬁ ve 
metabolic criteria, deﬁ ned on the basis of criteria from 
the Third Report of the National Cholesterol Education 
Program (NCEP),18 but with the cutoﬀ  for BMI suggested 
as an alternative to waist circumference in European 
criteria.19 Moreover, in a recent meta-analysis4 of 
43 studies, investigators recorded no heterogeneity 
(p=0·71) in relation to vascular risk dependent on whether 
the studies used waist, waist-hip ratio, or BMI in criteria 
for metabolic syndrome. Therefore use of BMI, at least in 
a dichotomous way, gives similar results to those for 
waist circumference.
Thus participants had metabolic syndrome if they 
fulﬁ lled three or more of the following: BMI of 30 kg/m² 
or more; triglyceride of 1·69 mmol/L or more; HDL 
cholesterol less than 1·04 mmol/L (men) or less than 
1·29 mmol/L (women); fasting glucose of 6·1 mmol/L or 
more; or blood pressure of 130/85 mm Hg or more, or 
receiving treatment for hypertension.
The British Regional Heart Study (BRHS)
On the basis of initial ﬁ ndings from PROSPER, we 
sought to corroborate data in a second prospective study 
that also ascertained events of both incident cardio-
vascular disease and diabetes. Furthermore, we wanted 
to include a study that used screening in the general 
population. BRHS is a prospective study of 
cardiovascular disease with 7735 men aged 40–59 years 
at baseline who were selected from the age-sex registers 
of one general practice in each of 24 UK towns, and 
who were screened between 1978 and 1980.16 The popu-
lation studied was socioeconomically representative of 
British men but consisted almost entirely of white 
Europeans (>99%). In 1998–2000, all surviving men, 
now aged 60–79 years, were invited for a 20th year 
follow-up examination. The men completed a 
questionnaire that included questions about their 
medical history and lifestyle behaviour. They were 
requested to fast for a minimum of 6 h, during which 
time they were instructed to drink only water and to 
attend for measurement at a prespeciﬁ ed time between 
0800 h and 1800 h. All men were asked to provide a 
blood sample, which was obtained with the Sarstedt 
Monovette system (Nuembrecht, Germany). 4252 men 
(77% of survivors) attended for examination. Men were 
asked to recall a doctor diagnosis of coronary heart 
disease (myocardial infarction or angina), stroke, 
diabetes, and other cardio vascular disorders.
Anthropometric measurements including body weight, 
height, and waist circumference were recorded and 
methods for lipids, blood pressure, and glucose have 
been described previously.20–22
All men have been followed up from initial examination 
(1978–80) to June, 2006, for all cause mortality and 
cardiovascular morbidity, and follow-up has been 
achieved for 99% people in the cohort.23 In the present 
analyses, all morbidity follow-up is based on follow-up 
from rescreening in 1998–2000 at a mean age 60–79 years, 
with a mean follow-up of 7 (range 6–8) years. Information 
about death was obtained through the established record 
linkage procedures provided by the UK National Health 
Service registers. Fatal stroke episodes were those coded 
on the death certiﬁ cate to 9th Revision of the International 
Classiﬁ cation of Diseases (ICD) codes 430–438. Events of 
non-fatal stroke were those which produced a neurological 
deﬁ cit that was present for more than 24 h. Fatal events 
of coronary heart disease were deﬁ ned as death with 
coronary heart disease (ICD codes 410–414) as the 
underlying code. A non-fatal myocardial infarction was 
diagnosed according to WHO criteria.24 Cardiovascular 
deaths included all those with ICD codes 401–459. 
Evidence for non-fatal coronary heart disease, angina, 
stroke, and diabetes was obtained by reports from family 
doctors and supplemented by reviews every 2 years of the 
Incident CVD Incident diabetes
Absent 
(n=2297)
Present 
(n=440)
p value Absent 
(n=2632)
Present 
(n=105)
p value
Age (years) 68·0 (5·39) 69·9 (5·66) <0·0001 68·3 (5·49) 68·2 (5·23) 0·88
Waist circumference 
(cm)
96·0 (9·79) 96·7 (10·12) 0·34 95·8 (9·67) 104·0 (10·97) <0·0001
Systolic BP 
(mm Hg)
148·3 (23·27) 155·8 (24·83) <0·0001 149·2 (23·65) 156·5 (23·37) 0·002
Diastolic BP 
(mm Hg)
85·8 (10·80) 87·2 (11·48) 0·05 85·9 (10·84) 89·7 (12·48) 0·0005
Fasting glucose 
(mmol/L)*
5·53 
(5·21–5·90)
5·53 
(5·22–5·90)
0·87 5·53 
(5·21–5·88)
6·00 
(5·58–6·52)
<0·0001
Total cholesterol 
(mmol/L)
6·08 (1·05) 6·10 (0·99) 0·42 6·08 (1·04) 6·14 (1·01) 0·58
HDL cholesterol 
(mmol/L)
1·36 (0·34) 1·30 (0·34) 0·0004 1·36 (0·34) 1·18 (0·32) <0·0001
LDL cholesterol 
(mmol/L)
3·95 (0·95) 4·01 (0·91) 0·12 3·96 (0·94) 3·95 (0·95) 0·91
Triglyceride 
(mmol/L)*
1·55 
(1·11–2·11)
1·62 
(1·20–2·17)
0·05 1·55 
(1·11–2·11)
2·01 
(1·53–2·74)
<0·0001
Smoking
Never 747 (33%) 118 (27%) 837 (32%) 28 (27%)
Former 1253 (55%) 257 (58%) 1443 (55%) 67 (64%)
Current 297 (13%) 65 (15%) 0·06 352 (13%) 10 (10%) 0·18
Data are mean (SD) or number (%). CVD=cardiovascular disease. BP=blood pressure. *For logged variables (triglyceride 
and glucose) IQR is provided.
Table 2: Comparison of baseline characteristics by incidence of cardiovascular disease and diabetes in 
British Regional Heart Study (BRHS)
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patients’ practice records (including hospital and clinic 
correspondence) that was undertaken through to the end 
of the study period, and from repeated personal 
questionnaires administered to surviving participants 
after initial examination.
In BRHS, both waist circumference and BMI were 
available, and so we used the original NCEP criteria with 
waist greater than 102 cm as one of the ﬁ ve cutoﬀ  points, 
with other endpoints the same as those in PROSPER.
Statistical analyses
In PROSPER, the prevalence of each metabolic factor, 
the distribution of the number of metabolic factors, and 
the prevalence of metabolic syndrome (three or more 
metabolic factors) are reported in subgroups that were 
deﬁ ned by the presence or absence of vascular disease at 
baseline. Kaplan-Meier estimates of the cumulative event 
rate in participants with or without the metabolic 
syndrome at baseline were used to report the incidence 
of events of cardiovascular disease and diabetes over a 
mean of 3·2 (range 2·8–4·0) years follow-up. 
Multivariable Cox proportional hazards models, with 
adjustment for age, sex, country, and treatment allocation 
(pravastatin or placebo), were used to estimate the hazard 
ratio associated with the presence of the metabolic 
syndrome, and every constituent metabolic factor at 
baseline, for events of cardiovascular disease and the 
endpoint of incident diabetes. In BRHS, the prevalence 
of every metabolic factor, the distribution of the number 
of metabolic factors, and the prevalence of metabolic 
syndrome (three or more metabolic factors) are reported. 
Cox’s proportional hazards model was used to assess the 
age-adjusted relative risks.
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
In PROSPER, we excluded a total of 760 participants with 
prevalent diabetes (626 with a known history of diabetes 
and 134 newly diagnosed patients with raised fasting 
glucose). An additional 232 participants had insuﬃ  cient 
information to be categorised at baseline. Therefore, 
4812 participants were included in this analysis. Of these 
participants, 287 developed new onset diabetes (209 of 
whom had no evidence of existing vascular disease and 
78 had vascular disease at baseline).
Table 1 shows that individuals in PROSPER who 
developed cardiovascular disease were older, more likely 
to be men, had a signiﬁ cantly lower HDL-cholesterol, 
and had greater prevalence of existing vascular disease 
than those who did not have disease, but BMI and fasting 
glucose or triglyceride concentrations did not diﬀ er. 
Individuals who subsequently developed diabetes had 
signiﬁ cantly higher baseline fasting glucose, BMI, 
triglyceride and systolic blood pressure, and lower 
HDL-cholesterol than did those who did not develop 
diabetes, but were not more likely to have vascular 
disease.
In BRHS, men with a doctor diagnosis of diabetes and 
those with a fasting glucose greater than 7 mmol/L were 
considered to have prevalent diabetes and were excluded 
(n=482). We further excluded men who self-reported a 
diagnosis of coronary heart disease (myocardial infarction 
or angina) or stroke (n=857) and those with missing 
components for the syndrome (n=176). After these 
exclusions, 2737 men were available for analysis. 327 events 
for coronary heart disease were recorded (myocardial 
infarction, angina, or death due to coronary heart 
disease), 440 events of cardiovascular disease (myocardial 
infarction, angina, stroke, all deaths due to cardiovascular 
disease), and 105 events of type 2 diabetes during the 
mean follow-up of 7 years.
Table 2 shows that individuals in BRHS who developed 
cardiovascular disease were older and more likely to have 
higher systolic blood pressure, a signiﬁ cantly lower 
HDL-cholesterol, and a higher triglyceride than were 
those who did not develop cardiovascular disease. 
However, waist circumference and fasting glucose did 
not diﬀ er between the groups that did or did not develop 
incident cardiovascular disease. Individuals who 
subsequently developed diabetes had signiﬁ cantly higher 
baseline fasting glucose, waist circumference, triglyceride 
and systolic blood pressure, and lower HDL-cholesterol 
than did those who did not develop diabetes.
Table 3 shows the prevalence of metabolic syndrome 
and its individual components in both PROSPER and 
BRHS. Overall, 1335 (28%) individuals satisﬁ ed the 
Metabolic syndrome BMI/waist* Triglyceride† HDL cholesterol‡ Fasting glucose§ Blood pressure¶
PROSPER (all [n=4812]) 1335 (27·7%) 916 (19·0%) 1423 (29·6%) 1892 (39·3%) 336 (7·0%) 4496 (93·4%)
PROSPER (no baseline CVD [n=3361]) 925 (27·5%) 685 (20·4%) 978 (29·1%) 1278 (38·0%) 238 (7·1%) 3169 (94·3%)
BRHS (men only [n=2737]) 744 (27·2%) 709 (25·9%) 1163 (42·5%) 509 (18·6%) 454 (16·6%) 2261 (82·6%)
Data are number (%). BMI=body-mass index. CVD=cardiovascular disease. PROSPER=Prospective Study of Pravastatin in the Elderly at Risk. BRHS=British Regional Heart 
Study. *BMI ≥30 kg/m2 or >102 cm. †Triglyceride ≥1·69 mmol/L. ‡HDL cholesterol <1·04 mmol/L (men) or <1·29 mmol/L (women). §Fasting glucose ≥6·1 mmol/L. ¶Systolic 
blood pressure ≥130 mm Hg, diastolic blood pressure ≥85 mm Hg, or treated hypertensive.
Table 3: Participants in PROSPER (all and those with no cardiovascular disease at baseline) and in BRHS who fulﬁ l each deﬁ nition of metabolic factor
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criterion for the metabolic syndrome in PROSPER of 
having at least three separate metabolic abnormalities at 
baseline. We recorded no evidence that people with or 
without existing vascular disease at baseline diﬀ ered with 
respect to the prevalence of metabolic syndrome (χ²=0·24, 
p=0·63; data not shown). Nor did we note any interaction 
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Figure: Cumulative event 
rates by presence or absence 
of metabolic syndrome and 
every metabolic factor at 
baseline, in participants 
without baseline vascular 
disease in PROSPER
(A) Events of cardiovascular 
disease. (B) Events of incident 
diabetes. Criteria were: BMI 
≥30 kg/m² ; triglyceride 
≥1·69 mmol/L; HDL 
cholesterol <1·04 mmol/L 
(men) or <1·29 mmol/L 
(women); fasting glucose 
≥6·1 mmol/L; and systolic 
blood pressure ≥130 mm Hg, 
diastolic blood pressure 
≥85 mm Hg, or treated 
hypertensive.
CVD=cardiovascular disease. 
BMI=body-mass index.
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of treatment allocation on any of the endpoints of interest 
(data not shown). In BRHS, 744 (27%) men had metabolic 
syndrome.
The ﬁ gure shows the Kaplan-Meier estimates of 
cumulative rates of cardiovascular disease and diabetes 
events in participants without existing vascular disease 
or diabetes at baseline in PROSPER, stratiﬁ ed by the 
metabolic syndrome and every component metabolic 
factor and adjusted for age, sex, country, and treatment 
allocation. This analysis shows that metabolic syndrome 
and most of its components are substantially associated 
with risk for new onset diabetes, but not with events of 
incident cardiovascular disease. The criterion of impaired 
fasting glucose (6·1–6·9 mmol/L) alone is linked to a 
pronounced increased risk of incident diabetes (ﬁ gure).
Table 4 provides the estimated hazard ratios associated 
with each component of the metabolic syndrome in those 
without vascular disease at baseline in both studies. In 
PROSPER we noted no association between events of 
cardiovascular disease and metabolic syndrome or 
individual metabolic factors. By contrast, metabolic 
syndrome, and each individual metabolic factor, was 
signiﬁ cantly associated with incident diabetes. The 
criterion of impaired fasting glucose showed an especially 
strong association with incident diabetes; despite only 
336 (7%) participants having impaired fasting glucose 
compared with 1335 (28%) having metabolic syndrome, 
the population attributable fraction was similar at 46% 
for impaired fasting glucose and 45% for metabolic 
syndrome. These ﬁ ndings were broadly similar in 
individuals with baseline vascular disease for whom 
metabolic syndrome was not associated with higher risk 
of cardiovascular disease events (HR 1·01 [95% CI 
0·79–1·28]) but was associated with diabetes risk (2·93 
[1·87–4·58]). We noted the same ﬁ nding for individual 
components (data not shown).
We related metabolic syndrome to coronary heart 
disease alone (coronary death or non-fatal myocardial 
infarction) in individuals without baseline vascular 
disease (the primary endpoint included stroke). The HR 
for coronary heart disease for metabolic syndrome was 
thus 1·11 (0·86–1·45), which accords with the results for 
total events of cardiovascular disease. The same ﬁ nding 
was also true for all individual components of the 
syndrome.
In BRHS, the metabolic syndrome was weakly 
associated with incident cardiovascular disease (relative 
risk [RR] 1·27 [1·04–1·56)]) despite being strongly related 
to diabetes (7·47 [4·90–11·46]; table 4). Additionally, three 
of the ﬁ ve components of metabolic syndrome did not 
predict risk of cardiovascular disease events—namely, 
raised waist circumference, triglyceride, or glucose—
whereas the other two cutoﬀ  points for HDL cholesterol 
and blood pressure were only modestly associated 
(table 4). By contrast, all ﬁ ve components were more 
strongly associated with risk of incident diabetes, with 
raised fasting glucose particularly strong (table 4).
Finally, when we used the 148 events of coronary heart 
disease speciﬁ cally (myocardial infarction or fatal death 
due to coronary heart disease), the age-adjusted relative 
risk was 1·20 (0·84–1·30), and the results for the 
individual components were much the same to that seen 
for all events of cardiovascular disease (data not shown).
Discussion
Results from this study show that metabolic syndrome 
has negligible clinical association with incident vascular 
events in elderly people despite strong associations with 
risk for incident type 2 diabetes in two prospective 
studies. Moreover, we have shown that the individual 
cutoﬀ  points in the criteria for metabolic syndrome 
predict risk of new onset diabetes with similar strength 
to data in younger populations,2,3 but results from 
PROSPER show that these cutoﬀ  points do not predict 
risk of vascular events in this population, irrespective of 
whether or not individuals had vascular disease at 
baseline. The ﬁ ndings were broadly similar when we 
extended analyses to the BRHS population-based study 
in men. Moreover, the same ﬁ nding was also true in 
both studies if we used coronary heart disease alone as 
the vascular endpoint. We noted that cutoﬀ  points for 
fasting glucose, triglyceride, and waist circumference 
had no association with risk of incident coronary heart 
disease in either study despite strong associations with 
incident diabetes. These ﬁ ndings suggest that the 
pattern of risk factors for new-onset diabetes diﬀ ers in 
many respects to that which predicts vascular events in 
elderly people.
Incident CVD Incident diabetes
PROSPER*
Number of events 434 209
Metabolic syndrome 1·07 (0·86–1·32) 4·41 (3·33–5·84)
BMI ≥30 kg/m² 0·99 (0·78–1·25) 2·51 (1·89–3·34)
Triglyceride ≥1·69 mmol/L 1·10 (0·90–1·35) 2·10 (1·60–2·77)
HDL cholesterol ≤1·04 mmol/L (men) or 
≤1·29 mmol/L (women)
1·15 (0·95–1·39) 2·09 (1·59–2·75)
Fasting glucose ≥6·1 mmol/L 0·94 (0·63–1·39) 18·42 (13·86–24·49)
BP ≥130/85 mm Hg or treatment 1·23 (0·79–1·92) 2·47 (1·02–6·02)
BRHS†
Number of events 440 105
Metabolic syndrome 1·27 (1·04–1·56) 7·47 (4·90–11·46)
Waist circumference >102 cm 1·08 (0·88–1·33) 3·86 (2·69–5·56)
Triglyceride ≥1·69 mmol/L 1·17 (0·97–1·40) 2·50 (1·68–3·71)
HDL cholesterol ≤1·04 mmol/L 1·46 (1·17–1·81) 3·49 (2·38–5·13)
Fasting glucose ≥6·1 mmol/L 1·05 (0·82–1·35) 5·97 (4·07–8·76)
BP ≥130/85 mm Hg or treatment 1·68 (1·26–2·24) 3·60 (1·68–7·74)
CVD=cardiovascular disease. BMI=body-mass index. BP=blood pressure. PROSPER=Prospective Study of Pravastatin in 
the Elderly at Risk. BRHS=British Regional Heart Study. *Adjusted for age, sex, country, and treatment allocation. 
†Adjusted for age.
Table 4: Hazard ratios (95% CIs) for events of cardiovascular disease and incident diabetes associated 
with metabolic syndrome, and individual criteria for metabolic syndrome
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Of wider relevance, our ﬁ ndings concur with data in 
middle-aged populations for whom criteria for metabolic 
syndrome are inferior to, and do not enhance conventional 
methods for, risk prediction of coronary heart disease.3,5 
For example, in the 20 year follow-up of the original 
BRHS3 (of men aged 40–59 years at baseline), the area 
under the ROC curve for prediction of events of coronary 
heart disease was 0·59 for metabolic syndrome versus 
0·68 for Framingham risk score. After adjustment for the 
Framingham risk score, metabolic syndrome was not 
associated with risk (RR 1·14 [95% CI 0·96–1·35]). Possible 
explanations for this weaker prediction are that the criteria 
for metabolic syndrome are more strongly aligned to new 
onset diabetes,2,3,10 use a weaker dichotomous design 
instead of continuous distributions of individual com-
ponents, and omit major risk factors for cardiovascular 
disease (eg, smoking). Thus, inclusion of strong diabetes, 
but, at best, weak predictors of cardiovascular disease—
namely, waist circumference or BMI, triglyceride, and 
glucose—in criteria for metabolic syndrome signiﬁ cantly 
attenuate associations to events of coronary heart disease, 
and even more so when these variables are dichotomised.
Although our results accord with a signiﬁ cant association 
between criteria for metabolic syndrome and incident 
diabetes in this elderly cohort, impaired fasting glucose 
alone was strongly linked to risk for incident diabetes in 
PROSPER, with nearly 50% of participants with a fasting 
glucose greater than 6·1 mmol/L progressing to develop 
overt diabetes. In BRHS, which included a younger cohort, 
fasting glucose alone was similar to metabolic syndrome 
in prediction of diabetes. The same ﬁ nding has been 
recorded in other studies such as an 8-year follow-up of 
the Framingham oﬀ spring population, in which the 
glucose cutoﬀ  was by far the best predictor of diabetes 
(RR 12·5 [95% CI 9·1–17·3]).25 Thus, metabolic syndrome 
per se, as presently deﬁ ned, is also not necessary or 
clinically needed to identify those at increased risk for new 
onset type 2 diabetes. Rather, if systematic screening for 
prevalent diabetes or high subsequent risk is ever widely 
adopted—and there is no guarantee it will—it will probably 
be a two stage process and targeted to those who are 
initially identiﬁ ed at substantially greater risk with use of 
simple questions (eg, age, family history of diabetes, 
ethnic origin, simple activity, and diet questions) combined 
with simple measurements (eg, BMI, waist, blood 
pressure). Thus, simple non-laboratory measures can be 
used to identify high-risk individuals before any blood 
sample—primarily for fasting or postprandial glucose 
measurements—is taken. In support of this approach, 
simple questionnaires show good prediction of diabetes 
risk in several cohorts.26,27
There are other implications of our ﬁ ndings. First, 
although metabolic syndrome as an entity might be of 
conceptual value, it has no beneﬁ t in risk stratiﬁ cation 
for cardiovascular disease in elderly people. This ﬁ nding 
is clinically relevant since most vascular events occur in 
individuals older than 60 years. Of course, the 
association of established cardiovascular risk factors 
with risk of vascular events is generally weaker in 
elderly populations (particularly LDL cholesterol, but 
also HDL cholesterol and blood pressure) than in 
middle-aged people, and our ﬁ ndings of even weaker 
associations of metabolic syndrome with incident 
vascular events is in keeping with this observation. 
Nevertheless, even though metabolic syndrome is 
modestly associated with risk of vascular events in 
middle-aged populations, the strength of independent 
association for events of coronary heart disease in 
cohorts without baseline disease—pooled RR of 1·49 
(1·37–1·61) in a recent meta-analysis4—is simply too 
weak to enhance risk prediction beyond established 
Framingham-based algorithms.3,5 This point is well 
made by Pepe and colleagues,28 who argue that a single 
measure of association such as an odds ratio does not 
meaningfully describe a marker’s (or in this case 
criteria’s) ability to classify patients.28
Second, previous studies have clearly shown that the 
sum of the components is not more than the individual 
parts of the syndrome with respect to risk prediction of 
cardiovascular disease:1,6,7,29 a ﬁ nding that we now extend 
to include two cohorts in the present report.
Third, although impaired fasting glucose (>6·1 mmol/L 
and <7·0 mmol/L) is a strong risk factor for development 
of type 2 diabetes, it seems not to be associated with risk 
for vascular events in elderly people, either in those with 
or without existing vascular disease. This ﬁ nding was 
noted in both studies, and re-emphasises that fasting 
glucose within the non-diabetes range is unlikely to be 
helpful in risk stratiﬁ cation for vascular events. Rather, 
the use of traditional risk factors is necessary for 
estimation of vascular risk in individuals without 
diabetes.
Fourth, the other major limitation of metabolic 
syndrome is of course the use of dichotomous cutoﬀ 
points. This limitation is notable in the example of HDL 
cholesterol in PROSPER or triglyceride in BRHS. In 
continuous analyses, HDL cholesterol is signiﬁ cantly 
lower in PROSPER participants who have a subsequent 
event, but not so with the dichotomous cutoﬀ  points that 
were chosen for the criteria for metabolic syndrome 
(table 3). Quintiles of HDL cholesterol are associated 
with risk in PROSPER,30 but clearly a simple dichotomous 
cutoﬀ  has reduced power. In BRHS, although triglyceride 
was higher in continuous analysis for events of 
cardiovascular disease, its signiﬁ cance was attenuated 
with the dichotomous approach. 
Finally, our work emphasises that patterns of risk 
factors related to development of new diabetes diﬀ er in 
many ways to those for vascular events. Thus, metabolic 
syndrome does not oﬀ er a common risk factor pathway 
or uniﬁ ed criteria to deﬁ ne risk for both diabetes and 
vascular disease.
Our study has several limitations and strengths. We 
acknowledge that the absence of an oral glucose toler-
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ance test means that some individuals will have 
developed type 2 diabetes which was not detectable by 
changes in fasting glucose alone or by clinical history. 
However, oral glucose tolerance tests for all participants 
over the course of PROSPER or BRHS were not feasible 
for pragmatic reasons and logistics. Our studies are not 
uncom mon in this respect, and in line with expectations, 
pre dictors of incident diabetes in both populations 
included the expected triad of fasting glucose, BMI or 
waist circumference, and triglyceride. We also acknow-
ledge that, as with BRHS, most studies reporting inci-
dent diabetes use doctor diagnosis plus participant 
self-report, and thus PROSPER is more thorough than 
are most other studies with additional biochemical 
conﬁ rmation.
We did not have waist circumference in PROSPER but 
did so in BRHS, and results were nearly identical. This 
ﬁ nding concurs with a recent meta-analysis reporting no 
diﬀ erence in outcomes irrespective of whether waist 
circumference or BMI were used in criteria for metabolic 
syndrome to predict events of cardiovascular disease.4 
Crucially, when treated in a dichotomous way, any 
anthropometric measure is either very weakly or not at all 
associated with risk of incident cardiovascular disease 
events. We also acknowledge that the data for blood 
pressure should be interpreted with caution, since the 
recruitment criteria for PROSPER required that individuals 
without hypertension had other risk factors. Nevertheless, 
somewhat consistent with our data for diastolic blood 
pressure, some other studies have reported higher 
mortality in the very elderly participants with lower 
diastolic blood pressure.31 We also recognise that we used 
criteria from the NCEP and not the International Diabetes 
Federation to test associations; however, a meta-analysis 
has shown that the NCEP-based deﬁ nition is better than 
IDF in its associations with vascular risk, albeit, and as 
discussed above, modestly so.4,32
We recognise that attrition bias could have led us to 
record slightly weaker associations of metabolic syndrome 
with events of cardiovascular disease in elderly people. 
However, we3 and others5 have shown that even in 
younger populations, metabolic syndrome is at best a 
modest predictor of events of coronary heart disease or 
cardiovascular disease, which is clearly worse than 
traditional algorithms that use continuous or categorical 
measures and which contain the key risk factors for 
cardiovascular disease: age, LDL cholesterol, and 
smoking. Thus our results are likely to be generalisable 
to adults of all relevant age groups.
With regards to strengths, the very similar ﬁ ndings in 
two independent prospective studies with diﬀ ering 
designs but both with ascertainment of incident 
cardiovascular disease and diabetes, provide substantial 
reassurance about the general validity of the data. 
PROSPER is a large study in terms of number of events 
that simultaneously tests the association of metabolic 
syndrome with events of cardiovascular disease and 
incident diabetes, and moreover, we were able to test 
associations in individuals with and without 
cardiovascular disease at baseline, showing clearly a 
closer association with diabetes. Although many risk 
variables lessen in their association with vascular events 
in elderly populations, a large number of new onset 
diabetes and vascular events (increasingly) occur in this 
population, and so the results have both clinical and 
scientiﬁ c value. 
Finally, our clear ﬁ nding in both studies of substantial 
diﬀ ering diabetes versus cardiovascular disease associa-
tions of metabolic syndrome and its components, should 
aid better general understanding of diﬀ ering risk 
patterns for these two diseases, which therefore should 
not be considered together. Our ﬁ ndings should help 
other investigators to think about their data in a similar 
critical way.
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